The TRIPs Agreement Amendment is faced with a lot of economic challenges. The production cost of compulsory licensing under the TRIPs Agreement Amendment is higher than one of the ordinary compulsory licensing. Whether the WTO members enforce the TRIPs Agreement Amendment is based on several economic factors：competing for marketing drug production cost， risk， market size， donation and the inclination which some generic pharmaceutical manufacturers are unwilling to manufacture and export drug in conformity with the TRIPs Agreement Amendment and the similar compulsory licensing regime.